MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, October 2, 2017

RebiSmart Usage Among Young, Less Disabled MS Patients May Improve with More Knowledge, Study Suggests

Relapsing-remitting multiple sclerosis (RRMS) patients accurately report the use of the RebiSmart autoinjector to their neurologists, a questionnaire-based study has found.
The Phase 4 noninterventional CORE study also suggests that being knowledgeable about RebiSmart is a key factor in improving usage in younger patients and those with lower disability levels.
The results, including questionnaires from 56 patients, were reported in a study, “Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart: the CORE study,” that appeared in the journal BMC Neurology.
The more an MS patient adheres to therapy, the more it may reduce the risk of relapse, disease progression and hospitalization. Adherence also improves quality of life while reducing MS-related medical costs.
Merck’RebiSmart device is an electronic, multidose autoinjector for subcutaneous self-injection of interferon (IFN) β-1a, which is known to reduce relapses. An electronic log-file system objectively monitors patients’ adherence to RebiSmart — which is crucial when deciding on alternative treatments for patients who stop taking RebiSmart.
In the Phase 4 CORE study, researchers at 11 sites in Switzerland compared RebiSmart’s recorded dosing history with adherence reported by patients to their neurologists. They found that patients accurately reported adherence to RebiSmart even during a median treatment duration of two years.
Researchers found that the high-adherence group included older patients (53 years vs. 41 years in the low adherence group) and with a greater expanded disability status scale (3 versus 1.5).

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 

No comments: